Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sleep Deprivation | 22 | 2024 | 846 | 4.100 |
Why?
|
| Sleep | 29 | 2024 | 4768 | 1.320 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 6 | 2024 | 1081 | 0.920 |
Why?
|
| Circadian Rhythm | 12 | 2019 | 2576 | 0.800 |
Why?
|
| Sleep, REM | 11 | 2019 | 595 | 0.650 |
Why?
|
| Baroreflex | 1 | 2019 | 149 | 0.590 |
Why?
|
| Autonomic Nervous System | 2 | 2024 | 703 | 0.480 |
Why?
|
| Receptors, Cytokine | 6 | 2001 | 258 | 0.480 |
Why?
|
| Narcolepsy | 7 | 1998 | 199 | 0.470 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 683 | 0.470 |
Why?
|
| Heart Rate | 6 | 2024 | 4195 | 0.440 |
Why?
|
| Sleep Phase Chronotherapy | 1 | 2012 | 4 | 0.430 |
Why?
|
| Blood Pressure | 5 | 2019 | 8481 | 0.430 |
Why?
|
| Inflammation | 10 | 2024 | 10774 | 0.370 |
Why?
|
| Sex Characteristics | 1 | 2021 | 2639 | 0.360 |
Why?
|
| Endotoxins | 9 | 2002 | 520 | 0.350 |
Why?
|
| Disorders of Excessive Somnolence | 2 | 2024 | 277 | 0.340 |
Why?
|
| Pain | 3 | 2012 | 5073 | 0.330 |
Why?
|
| Dinoprostone | 2 | 2009 | 597 | 0.330 |
Why?
|
| Pain Threshold | 2 | 2012 | 604 | 0.320 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 1190 | 0.300 |
Why?
|
| Clozapine | 8 | 2001 | 504 | 0.300 |
Why?
|
| Schools | 1 | 2016 | 1489 | 0.300 |
Why?
|
| Receptors, Interleukin-2 | 5 | 2004 | 562 | 0.280 |
Why?
|
| Learning | 1 | 2016 | 1740 | 0.280 |
Why?
|
| Polysomnography | 11 | 2024 | 1848 | 0.280 |
Why?
|
| Behavior Therapy | 1 | 2012 | 879 | 0.280 |
Why?
|
| C-Reactive Protein | 5 | 2024 | 3826 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2004 | 585 | 0.270 |
Why?
|
| Cardiovascular Diseases | 5 | 2021 | 15502 | 0.240 |
Why?
|
| Lipids | 1 | 2015 | 3341 | 0.230 |
Why?
|
| Cytokines | 12 | 2005 | 7396 | 0.230 |
Why?
|
| Neuroimmunomodulation | 4 | 2001 | 182 | 0.230 |
Why?
|
| Salmonella | 3 | 1999 | 125 | 0.230 |
Why?
|
| Informatics | 2 | 2022 | 72 | 0.220 |
Why?
|
| Hypertension | 4 | 2020 | 8540 | 0.220 |
Why?
|
| Sleep Stages | 5 | 2001 | 694 | 0.220 |
Why?
|
| Health Status | 2 | 2007 | 4077 | 0.220 |
Why?
|
| Affective Symptoms | 1 | 2005 | 417 | 0.210 |
Why?
|
| Sleep Medicine Specialty | 2 | 2013 | 71 | 0.210 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 1999 | 629 | 0.200 |
Why?
|
| Fatigue | 3 | 2023 | 1552 | 0.190 |
Why?
|
| Adult | 52 | 2024 | 221210 | 0.190 |
Why?
|
| Cross-Over Studies | 4 | 2024 | 2079 | 0.180 |
Why?
|
| Wakefulness | 7 | 2009 | 1265 | 0.170 |
Why?
|
| Interleukin-6 | 10 | 2016 | 3208 | 0.170 |
Why?
|
| Humans | 77 | 2024 | 761596 | 0.170 |
Why?
|
| Fatigue Syndrome, Chronic | 2 | 2001 | 215 | 0.170 |
Why?
|
| Women's Health | 1 | 2009 | 2065 | 0.170 |
Why?
|
| Pituitary-Adrenal System | 2 | 2019 | 552 | 0.160 |
Why?
|
| Reference Values | 5 | 2007 | 4920 | 0.160 |
Why?
|
| Male | 50 | 2024 | 360846 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2019 | 701 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2007 | 256 | 0.150 |
Why?
|
| Sleep Arousal Disorders | 1 | 1998 | 12 | 0.150 |
Why?
|
| Leptin | 2 | 2003 | 1597 | 0.150 |
Why?
|
| Hydrocortisone | 9 | 2016 | 1819 | 0.150 |
Why?
|
| Periodicity | 1 | 2019 | 348 | 0.140 |
Why?
|
| Chronobiology Disorders | 1 | 1998 | 73 | 0.140 |
Why?
|
| Antipsychotic Agents | 7 | 2001 | 3067 | 0.140 |
Why?
|
| Haloperidol | 2 | 1997 | 389 | 0.140 |
Why?
|
| Health Surveys | 2 | 2018 | 4061 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2023 | 907 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 12 | 2009 | 4352 | 0.130 |
Why?
|
| Respiration | 1 | 2023 | 1656 | 0.130 |
Why?
|
| Young Adult | 10 | 2024 | 59260 | 0.130 |
Why?
|
| Antigens, CD | 2 | 2004 | 4001 | 0.130 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2019 | 244 | 0.130 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1996 | 262 | 0.130 |
Why?
|
| Pain Measurement | 3 | 2012 | 3551 | 0.120 |
Why?
|
| Achievement | 1 | 2016 | 288 | 0.120 |
Why?
|
| Female | 38 | 2024 | 392705 | 0.120 |
Why?
|
| Time | 1 | 2016 | 546 | 0.120 |
Why?
|
| Cataplexy | 2 | 1997 | 61 | 0.120 |
Why?
|
| Catalepsy | 1 | 1993 | 31 | 0.110 |
Why?
|
| Melatonin | 1 | 2019 | 669 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2006 | 2206 | 0.110 |
Why?
|
| Motivation | 1 | 2023 | 2006 | 0.110 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 633 | 0.110 |
Why?
|
| Reaction Time | 5 | 2005 | 2089 | 0.110 |
Why?
|
| Leukocyte Count | 6 | 2000 | 1596 | 0.110 |
Why?
|
| Schizophrenia | 9 | 1998 | 6937 | 0.100 |
Why?
|
| Advisory Committees | 2 | 2014 | 787 | 0.100 |
Why?
|
| Aspirin | 1 | 2024 | 3133 | 0.100 |
Why?
|
| Occupational Health | 1 | 2019 | 806 | 0.100 |
Why?
|
| Human Growth Hormone | 2 | 1999 | 642 | 0.100 |
Why?
|
| Immersion | 1 | 2012 | 37 | 0.100 |
Why?
|
| Middle Aged | 20 | 2024 | 220921 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 1886 | 0.100 |
Why?
|
| Body Temperature | 8 | 2000 | 781 | 0.100 |
Why?
|
| Electroencephalography | 6 | 2019 | 6237 | 0.100 |
Why?
|
| Venoms | 1 | 2011 | 94 | 0.090 |
Why?
|
| Accidents, Traffic | 1 | 2016 | 816 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 2 | 2002 | 258 | 0.090 |
Why?
|
| Acute-Phase Reaction | 1 | 2010 | 91 | 0.090 |
Why?
|
| Fever | 5 | 2000 | 1618 | 0.090 |
Why?
|
| Schools, Medical | 2 | 2013 | 879 | 0.080 |
Why?
|
| Prostaglandins | 2 | 2009 | 398 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2004 | 344 | 0.080 |
Why?
|
| Pressure | 1 | 2012 | 1154 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2016 | 1403 | 0.080 |
Why?
|
| Goals | 1 | 2014 | 711 | 0.080 |
Why?
|
| Immune System | 3 | 2005 | 796 | 0.080 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2007 | 8 | 0.080 |
Why?
|
| Foot | 1 | 2012 | 575 | 0.070 |
Why?
|
| Homeostasis | 1 | 2019 | 3323 | 0.070 |
Why?
|
| Time Factors | 8 | 2018 | 39969 | 0.070 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 108 | 0.070 |
Why?
|
| Healthy People Programs | 2 | 2019 | 54 | 0.070 |
Why?
|
| Biomedical Research | 4 | 2019 | 3429 | 0.070 |
Why?
|
| Health Promotion | 1 | 2019 | 2214 | 0.070 |
Why?
|
| Body Temperature Regulation | 2 | 2000 | 292 | 0.070 |
Why?
|
| Students | 1 | 2016 | 1741 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2012 | 1440 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2012 | 1988 | 0.060 |
Why?
|
| Single-Blind Method | 5 | 2000 | 1574 | 0.060 |
Why?
|
| Animals | 7 | 2021 | 168475 | 0.060 |
Why?
|
| Comorbidity | 3 | 2024 | 10508 | 0.060 |
Why?
|
| Proteins | 1 | 1999 | 6032 | 0.060 |
Why?
|
| Sialoglycoproteins | 3 | 2000 | 315 | 0.060 |
Why?
|
| Health Behavior | 1 | 2015 | 2644 | 0.060 |
Why?
|
| Endotoxemia | 2 | 2006 | 196 | 0.060 |
Why?
|
| Neutrophils | 1 | 1996 | 3767 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2019 | 12794 | 0.060 |
Why?
|
| Bacterial Toxins | 3 | 2000 | 932 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 3 | 2000 | 299 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 1882 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3808 | 0.050 |
Why?
|
| Adolescent | 7 | 2023 | 88326 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 4575 | 0.050 |
Why?
|
| Electromyography | 2 | 2000 | 1394 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2014 | 3905 | 0.050 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 2001 | 7 | 0.050 |
Why?
|
| Affect | 1 | 2009 | 1486 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 290 | 0.050 |
Why?
|
| Psychomotor Disorders | 1 | 2001 | 149 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 10554 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2016 | 4481 | 0.040 |
Why?
|
| Electrooculography | 1 | 2000 | 113 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2000 | 241 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 983 | 0.040 |
Why?
|
| Peptides | 1 | 2011 | 4358 | 0.040 |
Why?
|
| Causality | 1 | 2005 | 1242 | 0.040 |
Why?
|
| Risk Factors | 5 | 2018 | 74213 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2012 | 8633 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5872 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 3085 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 9319 | 0.040 |
Why?
|
| Obesity | 2 | 2011 | 12947 | 0.040 |
Why?
|
| HLA-DR2 Antigen | 1 | 1998 | 44 | 0.040 |
Why?
|
| Fibromyalgia | 2 | 2001 | 405 | 0.040 |
Why?
|
| Arousal | 2 | 2001 | 1166 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1702 | 0.040 |
Why?
|
| Space Flight | 1 | 2001 | 215 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 26129 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 1379 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1998 | 6345 | 0.040 |
Why?
|
| Aging | 1 | 1996 | 8710 | 0.040 |
Why?
|
| Immunoassay | 1 | 2001 | 745 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12341 | 0.040 |
Why?
|
| Secretory Rate | 1 | 1996 | 81 | 0.030 |
Why?
|
| Caffeine | 1 | 2001 | 700 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 1188 | 0.030 |
Why?
|
| Canada | 1 | 2022 | 2122 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3688 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2010 | 3964 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1779 | 0.030 |
Why?
|
| Memory | 1 | 2005 | 2193 | 0.030 |
Why?
|
| Boston | 1 | 2009 | 9327 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2004 | 6228 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2023 | 1808 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 3492 | 0.030 |
Why?
|
| Schizophrenic Psychology | 3 | 1997 | 1647 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 1997 | 3728 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2015 | 209 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2273 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2009 | 6391 | 0.030 |
Why?
|
| Neural Inhibition | 1 | 1997 | 590 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 1177 | 0.030 |
Why?
|
| Workplace | 1 | 2019 | 863 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2023 | 41495 | 0.020 |
Why?
|
| Sepsis | 1 | 2006 | 2585 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2023 | 5247 | 0.020 |
Why?
|
| Risk | 1 | 2004 | 9610 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2002 | 10766 | 0.020 |
Why?
|
| Receptors, Glucagon | 1 | 2011 | 90 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2013 | 426 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 1875 | 0.020 |
Why?
|
| Electrodes | 1 | 1993 | 614 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1998 | 2612 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2023 | 3415 | 0.020 |
Why?
|
| United States | 5 | 2018 | 72340 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1802 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2023 | 54423 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 1993 | 763 | 0.020 |
Why?
|
| Shock, Septic | 1 | 1996 | 768 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2003 | 3980 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 679 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15733 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2011 | 935 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 1998 | 397 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2010 | 23447 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 1139 | 0.020 |
Why?
|
| Monocytes | 1 | 2016 | 2570 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1996 | 1590 | 0.020 |
Why?
|
| Disease Progression | 1 | 2023 | 13510 | 0.020 |
Why?
|
| Veterans | 1 | 2020 | 2649 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 64685 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15843 | 0.020 |
Why?
|
| Cecum | 1 | 2006 | 233 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2005 | 147 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2006 | 222 | 0.020 |
Why?
|
| Dreams | 1 | 1986 | 146 | 0.010 |
Why?
|
| Interleukin-1 | 2 | 1998 | 1248 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 23996 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 13367 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3322 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1421 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2002 | 21 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2002 | 861 | 0.010 |
Why?
|
| Incidence | 1 | 2020 | 21355 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18399 | 0.010 |
Why?
|
| Interleukin-2 | 2 | 1998 | 1889 | 0.010 |
Why?
|
| Acetone | 1 | 2000 | 44 | 0.010 |
Why?
|
| Longitudinal Studies | 4 | 1998 | 14608 | 0.010 |
Why?
|
| Endocrine Glands | 1 | 2000 | 102 | 0.010 |
Why?
|
| Hydrazones | 1 | 2000 | 103 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1998 | 3810 | 0.010 |
Why?
|
| Weight Loss | 1 | 2011 | 2684 | 0.010 |
Why?
|
| Smoking | 1 | 1997 | 9053 | 0.010 |
Why?
|
| Self Concept | 1 | 1986 | 1045 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1704 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 2005 | 982 | 0.010 |
Why?
|
| Solubility | 1 | 2001 | 1091 | 0.010 |
Why?
|
| Aged | 2 | 2024 | 169310 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 2395 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 3358 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 1 | 1998 | 93 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1997 | 167 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1998 | 712 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1995 | 97 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 1996 | 269 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1996 | 618 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 80647 | 0.010 |
Why?
|
| Rectum | 1 | 1999 | 892 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 58984 | 0.010 |
Why?
|
| Interleukins | 1 | 1996 | 782 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 7054 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1998 | 2118 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1995 | 718 | 0.000 |
Why?
|
| Rabbits | 1 | 1995 | 4772 | 0.000 |
Why?
|
| Cognition | 1 | 1986 | 6992 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 5485 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1997 | 6019 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 27121 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18255 | 0.000 |
Why?
|
| Models, Biological | 1 | 2003 | 9469 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1995 | 1391 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 12059 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1998 | 18966 | 0.000 |
Why?
|
| Brain Mapping | 1 | 1997 | 6635 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1997 | 5779 | 0.000 |
Why?
|
| Consciousness | 1 | 1986 | 601 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 81539 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 23741 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1995 | 6845 | 0.000 |
Why?
|
| HIV Infections | 1 | 1995 | 17354 | 0.000 |
Why?
|
Concepts
(267)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(48)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_